ERCC1, KRAS mutation, redox status, and oxaliplatin sensitivity in colorectal cancer: “Radical” change in an old model.

Armando Orlandi,Mariantonietta Di Salvatore,Michele Basso,Cinzia Bagalà,Antonia Strippoli,Francesca Plastino,Enzo Dadduzio,Simona Di Lascio,Elisabetta Cursio,Alessia Amoruso,Mariagrazia Rodriquenz,Alessandra Cassano,A. Astone,Carlo Barone

ERCC1, KRAS mutation, redox status, and oxaliplatin sensitivity in colorectal cancer: “Radical” change in an old model.

2017

Armando Orlandi
Mariantonietta Di Salvatore
Michele Basso
Cinzia Bagalà
Antonia Strippoli
Francesca Plastino
Enzo Dadduzio
Simona Di Lascio
Elisabetta Cursio
Alessia Amoruso
Mariagrazia Rodriquenz
Alessandra Cassano
A. Astone
Carlo Barone

e14156 Background: Oxaliplatin (Oxa) is widely used in metastatic colorectal cancer, but currently there are not valid predictors of response to this drug. In our recent retrospective clinical stud...

Keywords:

Pathology
Oxaliplatin
KRAS
Oncology
Colorectal cancer
Mutation
Drug
ERCC1
Internal medicine
Medicine
redox status
kras mutation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations